Form 4: Electromed Director Sells Shares in Portfolio Diversification

Electromed director Kathleen Skarvan sold a total of 149,999 shares of common stock across multiple transactions on November 18th and 19th, 2024, as part of a portfolio diversification strategy.

Summary

• Kathleen Skarvan, a director at Electromed, Inc., sold a significant number of shares of the company's common stock.
• The sales occurred over two days, November 18th and 19th, 2024.
• On November 18th, 42,453 shares were sold at a weighted average price of $28.1641 per share.
• On November 19th, two separate sales occurred: 50,602 shares at a weighted average price of $27.9221 per share and 56,945 shares at a weighted average price of $27.9706 per share.
• The total number of shares sold was 149,999.
• These sales were part of a diversification of the reporting person's securities portfolio and individual financial and retirement planning.
• Following these transactions, Ms. Skarvan directly owns 52,394 shares and indirectly owns 28,989 shares through a trust.

Sentiment

Score: 5

Explanation: The document reflects a routine insider sale for portfolio diversification, which is neither particularly positive nor negative. The sentiment is neutral.

Risks

• Large sales by insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Management Comments

• The sales are part of a diversification of the reporting person's securities portfolio and individual financial and retirement planning.

Industry Context

Insider sales are a common occurrence, and this transaction is not unusual for a director managing their personal portfolio. It is important to monitor if other insiders are also selling shares.

Comparison to Industry Standards

• It is common for directors to sell shares for personal financial planning, and the size of this sale is not unusual for a director's portfolio.
• Comparable companies often see similar insider transactions, and the key is to monitor the overall trend of insider activity.

Stakeholder Impact

• The sale of shares by a director could potentially cause a slight negative reaction from shareholders, but it is not expected to have a significant impact.

Key Dates

Keywords

Electromed, ELMD, insider trading, stock sale, Kathleen Skarvan, portfolio diversification, director